News for DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischem

DiaMedica Therapeutics Inc. (DMAC) to present at the Jefferies Global Healthcare Conference 2025. Presentation scheduled for June 4, 2025, at 12:50 PM E

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced toda

DiaMedica Therapeutics Inc. (DMAC) to host a virtual Key Opinion Leader event on May 28, 2025, focusing on preeclampsia. The event will spotlight DM199,

May 14, 2025 / 12:00PM GMTOperator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics first quarter 2025 conference call. An audio re

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ETCompany ParticipantsRick Pauls - President and Chief...

DiaMedica Therapeutics (DMAC) is poised for a significant milestone as the company anticipates the release of initial safety and efficacy data from Part 1A of t

DiaMedica Therapeutics (DMAC) reports a net loss of $7.7 million for Q1 2025, compared to $5.2 million in Q1 2024. The company anticipat

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, ann

Maine-based Synergy CHC Corp. (SNYR) is up over 139 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Shares of Telefonaktiebolaget LM Ericsson ERIC rose sharply in today's pre-market trading following first-quarter results. Ericsson reported that its first-qua...

Cash and Investments: $44.1 million as of December 31, 2024.Current Liabilities: $5.4 million as of December 31, 2024.Working Capital: $39.2 million as of Dece

Mar 18, 2025 / 12:00PM GMTRick Pauls - DiaMedica Therapeutics Inc - President, Chief Executive Officer, Director Thank you, operator. Hello everyone and welcome

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ETCompany ParticipantsRick Pauls - President and...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and pre

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, ann

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the e

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsRick Pauls - President, Chief...